Doctors call for shorter gap between Pfizer Covid vaccine doses in UK
January 23, 2021, 12:06 pm

Doctors call for shorter gap between Pfizer Covid vaccine doses in UK

Pfizer has said it only tested the vaccine’s efficacy when the two doses were given 21 days apart.

British Medical Council warns current 12-week wait could reduce effectiveness of the jab

The gap between the first and second dose of the Pfizer/BioNTech coronavirus vaccine must be reduced to ensure the vaccine is effective, senior doctors have warned.

Currently patients wait about three months to get their second dose. Prof Chris Whitty, the chief medical officer for England, said this was a “public health decision” to get the first jab to more people across the country.

However, Dr Chaand Nagpaul, chair of the council of the British Medical Association (BMA), said the gap could reduce the effectiveness of the vaccine. He said that while he understood the rationale behind the decision to delay the second dose, the UK should follow “best practice” and reduce the wait time to six weeks.While there is some evidence from trials of the Oxford/AstraZeneca vaccine that a late second dose up to 12 weeks does not interfere with the efficacy of the vaccine, Pfizer has said there is no evidence from its trials.

Nagpaul pointed to analysis from the World Health Organization that said second doses of the Pfizer vaccine should only be delayed “in exceptional circumstances” and recommended a gap of four weeks between doses.

“Most nations in the world are facing challenges similar to the UK in having limited vaccine supply and also wanting to protect their population maximally. No other nation has adopted the UK’s approach,” Nagpaul told BBC Breakfast on Saturday.

“Obviously the protection will not vanish after six weeks but what we do not know is what level of protection will be offered … we should not be extrapolating data where we don’t have it. I do understand the trade-off and the rationale but if that was the right thing to do then we would see other nations following suit.

“The concern we have … if the vaccine’s efficacy is reduced … then of course the risk is that we will see those who are exposed maximally to the virus may get infected,” he added. “The other worry is that members of the population, those who are at highest risk, may not be protected.”

According to the government’s Joint Committee on Vaccination and Immunisation, unpublished data suggests the Oxford/AstraZeneca vaccine is still effective when the doses are administered 12 weeks apart. However, Pfizer said it had only tested the vaccine’s efficacy when the two doses were given up to 21 days apart.

The BMA has written privately to Whitty to express its concern over the gap between doses. The letter, seen by the BBC, said the policy was “difficult to justify”.

“The absence of any international support for the UK’s approach is a cause of deep concern and risks undermining public and the profession’s trust in the vaccination programme,” it said.

The letter also expressed concern that one dose of the Pfizer vaccine “does not produce sufficient neutralising antibodies and the potential to reduce transmission”.

The Public Health England medical director, Prof Yvonne Doyle, defended the decision to delay the vaccine, saying it was based on “public health and scientific advice”.

“The more people that are protected against this virus, the less opportunity it has to get the upper hand. Protecting more people is the right thing to do,” she told BBC Radio 4’s Today programme.

“People will get their second dose. As supplies become available more people will be vaccinated. It is a reasonable scientific balance on the basis of both supply and also protecting the most people.”

The NHS originally planned to offer second shots of the Pfizer vaccine three weeks after the first, in line with the procedure in the trials, but the soaring infection rate forced a rethink in late December with the JCVI recommending first shots for as many people as possible in the highest-risk groups.

“This is highly likely to have a greater public health impact in the short term and reduce the number of preventable deaths from Covid-19,” a JCVI statement said.

source: Molly Blackall

Levant

Coronavirus: Iran to begin COVID-19 vaccine in weeks Too early to say': scientists unsure if UK Covid variant is more deadly

BENEFIT, the Kingdom’s innovator and leading company in Fintech and electronic financial transactions service, has announced its sponsorship of the “Innovation and Sustainable Technology Solutions Competition (GU - IST Solutions), hosted by Gulf University at its main campus.
This strategic sponsorship reflects BENEFIT’s active role in advancing technological innovation and fostering sustainable solutions to future challenges. It also seeks to empower Bahraini youth by enhancing their skills, capabilities, and competitiveness in innovation and solution development—contributing meaningfully to the broader goals of sustainable development across all sectors.
As part of BENEFIT’s active involvement in the competition, the company has announced that Hanan Abdulla Hasan, Senior Manager of Public Relations and Communication, will serve on the competition’s supervisory committee. Her upcoming participation reflects BENEFIT’s forward-looking commitment to championing academic and professional excellence.
Commenting on the occasion, Hanan Abdulla Hasan, Senior Manager of Public Relations and Communication at BENEFIT, said, “We are privileged to support this pioneering initiative, which aligns seamlessly with BENEFIT’s enduring commitment to fostering innovation and nurturing the potential of Bahrain’s youth. Our participation is rooted in a deep sense of social responsibility and a firm belief in the pivotal role of innovation in shaping a sustainable future. Through such platforms, we seek to empower the next generation with the knowledge, skills, and foresight required to develop impactful solutions that address future challenges, in line with the United Nations Sustainable Development Goals 2030.”
Dr. Aseel Al Ayash Dean of the College of Engineering in Gulf University commented, “We extend our sincere gratitude to BENEFIT for their generous sponsorship and support of the Innovation and Sustainable Technology Solutions Competition. This contribution plays an instrumental role in helping us achieve the strategic goals of this initiative, namely, cultivating a culture of innovation and sustainability, encouraging efforts that address the imperatives of sustainable development, and enhancing the practical and professional capabilities of our students and participants.”
The event will bring together a diverse spectrum of participants, including secondary school students, university undergraduates, engineers, industry professionals, entrepreneurs, academic researchers, and subject matter experts representing a wide range of disciplines.
The competition seeks to inspire participants to develop and present innovative, sustainable technologies aimed at addressing pressing environmental, social, and economic challenges. It encourages the formulation of business models that integrate advanced technological solutions with core principles of sustainability. Moreover, it serves as a platform for emerging leaders, entrepreneurs, and innovators to contribute to the advancement of the Sustainable Development Goals, promote the ethos of responsible technology, and demonstrate its transformative potential across various sectors.
Attendees will have the opportunity to view a series of project presentations submitted by participants, covering diverse areas such as eco-friendly product design, smart and sustainable innovations, renewable energy technologies, water conservation and management, waste minimisation and recycling, green architectural solutions, and sustainable transportation systems. Outstanding projects will be formally recognised and awarded at the conclusion of the event.